[Federal Register Volume 63, Number 72 (Wednesday, April 15, 1998)]
[Notices]
[Pages 18427-18430]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-9909]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Announcement 98023]
Human Immunodeficiency Virus (HIV), Sexually Transmitted Diseases
(STDs), and Tuberculosis (TB) Related Applied Research Projects
A. Purpose
The Centers for Disease Control and Prevention (CDC) announces the
availability of funds beginning in fiscal year (FY) 1998 for
cooperative agreements to conduct human immunodeficiency virus (HIV),
sexually transmitted diseases (STDs), and tuberculosis (TB) related
applied research into the control and prevention of HIV, STDs and TB.
The purpose of this program is to encourage new and innovative methods
to further the prevention of HIV, STDs and TB infection. Projects that
will be considered for funding are applied research into the control
and prevention of HIV, STDs, or TB. This program addresses the
``Healthy People 2000'' priority area(s) HIV Infection, Sexually
Transmitted Diseases, and Immunization and Infectious Diseases.
National Program Goals
CDC's national strategic goals for the programs supported by the
National Center for HIV, STDs and TB Prevention are:
1. Increase public understanding of, involvement in, and support
for HIV, STDs, and TB prevention.
2. Ensure completion of therapy for persons identified with active
TB or TB infection.
3. Prevent or reduce behaviors or practices that place persons at
risk for HIV and STDs infection or, if already infected, place others
at risk.
4. Increase individual knowledge of HIV serostatus and improve
referral systems to appropriate prevention and treatment services.
5. Assist in building and maintaining the necessary State, local,
and community infrastructure and technical capacity to carry out
necessary prevention programs.
6. Strengthen the current systems and develop new systems to
accurately monitor HIV, STDs, and TB, as a basis for assessing and
directing prevention programs.
B. Eligible Applicants
Eligible applicants will include universities, colleges, research
institutions, hospitals, public and
[[Page 18428]]
private non-profit organizations, community-based, national, and
regional organizations, State and local governments or their bona fide
agents or instrumentalities, federally recognized Indian Tribal
governments, Indian tribes or organizations, and small, minority-and/or
women owned non-profit businesses.
Note: Organizations described in section 501(c)(4) of the
Internal Revenue Code of 1986 that engage in lobbying are not
eligible to receive Federal grant/cooperative agreement funds.
C. Availability of Funds
Approximately $500,000 is available in FY 1998 to fund
approximately four awards. It is expected that the average award will
be $150,000, ranging from $100,000--$300,000. Funding estimates are
subject to change. It is expected that awards will begin in September,
1998 and will be made for a 12 month budget period within a project
period of up to three years. Funding will be available during the
fiscal year for applications submitted that are consistent with the
National Center for HIV, STD, and TB Prevention (NCHSTP) National
Program Goals. Funding estimates are subject to change. Continued
support in future years will be based on the availability of funds and
success in demonstrating progress toward achievement of objectives.
Program Priority Areas
1. The impact of managed care on TB control activities.
2. The impact of behavioral intervention in correctional settings
on the community at large or the impact of corrections, public health,
and substance abuse collaborations on the health of the community.
3. The impact of peer and community education programs on health
seeking behaviors of high risk populations, women, youth, and substance
abusers.
4. Correctional health care, especially the impact of managed care
or privatized care providers, and its impact on health care utilization
in the community.
5. The relationship between drug and alcohol use and sexual
behavior and high risk sexual behavior among IDUs, sexual partners of
IDUs, women, adolescents, and men who have sex with men.
6. The evaluation of non-abstinence based strategies for drug users
who cannot or are unwilling to stop drug use.
7. The development, piloting, evaluation, or technology transfer of
innovative behavioral interventions designed to reduce the transmission
or acquisition of HIV among vulnerable populations.
8. The development of new methods for estimating HIV incidence,
assessment of HIV incidence in selected, high-risk populations or
social networks in geographically-defined communities where HIV
incidence is known or expected to be high, or use of HIV incidence data
for evaluating prevention interventions.
9. The development, evaluation, or improvement of HIV prevention
interventions.
10. Develop a knowledge base to improve access to care of HIV-
infected persons and to reduce HIV-associated morbidity and mortality
among persons in care.
11. Among HIV-infected persons in care, prevent development of
opportunistic infections and prevent/delay progression to AIDS and
death.
CDC may announce additional priority areas through both the Federal
Register and the Internet.
D. Program Requirements
1. Recipient activities to achieve the purposes of this program
will vary by project. CDC will be responsible for the activities under
CDC Activities.
1. Recipient Activities
A. Complete the development of the research protocol.
B. Carry out the activities according to the approved protocol.
C. Ensure that appropriate approvals are secured for the protection
of human subjects, Office of Management and Budget and Paperwork
Reduction Act, privacy, confidentiality, and data security.
D. Compile and disseminate findings.
2. CDC Activities
A. Monitor and evaluate scientific and operational accomplishments
of the project through periodic site visits, frequent telephone calls,
and review of technical reports and interim data analysis.
B. For recipients whose project involves collaboration with a State
or local health department, CDC will assist in facilitating the
planning and implementation of the necessary linkages with local or
State health departments and assist with the developmental strategies
for applied clinical or prevention oriented research programs.
C. Facilitate the technological and methodological dissemination of
successful prevention and intervention models among appropriate target
groups, such as, State and local health departments, community based
organizations, and other health professionals.
D. Participate in planning, implementing, and evaluating strategies
and protocols.
E. Application Content
1. Letter of Intent (LOI)
Potential applicants must submit an original and two copies of a
two-page typewritten Letter of Intent (LOI) that briefly describes the
title of the project, purpose and need for the project as well as its
relationship to the National Program Goals, the estimated total cost of
the proposed project, and the dollar amount and percentage of the total
cost being requested from CDC. Current recipients of CDC funding must
provide the award number and title of the funded programs. No
attachments, booklets, or other documents accompanying the LOI will be
considered.
LOI's will be reviewed by CDC program staff and an invitation to
submit a full application will be made based on the documented need for
the proposed project, contribution to the NCHSTP National Program
Goals, and the availability of funds. LOI's may focus individually on
HIV, STD, or TB, or may address more than one programmatic priority
area.
An invitation to submit a full application does not constitute a
commitment by CDC to fund the applicant.
2. Application
Applications may be submitted only after a Letter of Intent has
been approved by CDC and a written invitation from CDC has been
extended to the prospective applicant. Applicants who are invited to
submit a full application must use Form PHS 398 (OMB Number 0925-0001),
and submit an original and five copies. The application narrative
should consist of:
A. Abstract (Not to exceed 1 page): An executive summary of your
program covered under this announcement.
B. Program Plan (Not to exceed 10 pages): In developing the
application under this announcement, please review the recipient
activities and, in particular, evaluation criteria and respond
concisely and completely.
C. Budget: Submit an itemized budget and supporting justification
that is consistent with your proposed program plan.
[[Page 18429]]
F. Submission Requirements and Deadlines
1. Letter of Intent (LOI)
ONE ORIGINAL AND TWO COPIES of the LOI must be postmarked on or
before May 18, 1998. (FACSIMILES ARE NOT ACCEPTABLE.)
2. Application
ONE ORIGINAL AND FIVE COPIES of the invited applications must be
submitted on Form PHS 398 (OMB Number 0925-0001) and must be postmarked
on or before July 20, 1998.
3. Address for Submission of Letter of Intent and Invited Application
Juanita Dangerfield, Grants Management Specialist, Grants
Management Branch, Centers for Disease Control and Prevention (CDC),
255 East Paces Ferry Road NE., Room 300, Mailstop E-15, Atlanta,
Georgia 30305
4. Application Deadline
Letters of Intent and Applications shall be considered as meeting
the deadline if they are either:
a. Received on or before the deadline date, or
b. Postmarked on or before the deadline date and received in time
for submission to the objective review committee. (Applicants must
request a legibly dated U.S. Postal Service postmark or obtain a
legibly dated receipt from a commercial carrier or U.S. Postal Service.
Private metered postmarks shall not be acceptable as proof of timely
mailing.)
5. Late Applications and Letters of Intent
Applications that do not meet the criteria in 4a or 4b are
considered late applications and will be returned to the applicant
without review.
G. Evaluation Criteria
Applications responding to this announcement will be evaluated
individually according to the following criteria.
1. The inclusion of a brief review of the scientific literature
pertinent to the study being proposed and specific research questions
or hypotheses that will guide the research. The originality and need
for the proposed research, the extent to which it does not replicate
past or present research efforts, and how findings will be used to
guide prevention and control efforts. (20 points)
2. The quality of the plans to develop and implement the study,
including the degree to which the applicant has met the CDC Policy
requirements regarding the inclusion of women, ethnic, and racial
groups in the proposed research. This includes:
a. The proposed plan for the inclusion of both sexes and racial and
ethnic minority populations for appropriate representation.
b. The proposed justification when representation is limited or
absent.
c. A statement as to whether the design of the study is adequate to
measure differences when warranted.
d. A statement as to whether the plans for recruitment and outreach
for study participants include the process of establishing partnerships
with community(ies) and recognition of mutual benefits. (20 points)
3. Extent to which proposed objectives will further the NCHSTP
National Program Goals. (20 points)
4. Extent to which proposed activities, if well executed, are
capable of attaining project objectives. (20 points)
5. Extent to which personnel involved in this project are
qualified, including evidence of past achievements appropriate to the
project and realistic and sufficient percentage-time commitments.
Evidence of adequacy of facilities and other resources needed to carry
out the project. (20 points)
6. Other (not scored)
a. Budget: Will be reviewed to determine the extent to which it is
reasonable, clearly justified, consistent with the intended use of the
funds, and allowable. All budget categories should be itemized.
b. Human Subjects: Whether or not exempt from the Department of
Health and Human Services regulations, are procedures adequate for the
protection of human subjects? Recommendations on the adequacy of
protections include the following:
(1) Protections appear adequate and there are no comments to make
or concerns to raise, (2) protections appear adequate, but there are
comments regarding the protocol, (3) protections appear inadequate and
the Objective Review Group (ORG) has concerns related to human
subjects; or (4) disapproval of the application is recommended because
the research risks are sufficiently serious and protection against the
risks are inadequate as to make the entire application unacceptable.
Funding decisions on approved applications will depend on the area
of interest of the proposals, their relationship to NCHSTP National
Program Goals, the specific research questions being proposed, and the
quality of the application.
H. Other Requirements
Technical Reporting Requirements
Provide CDC with original plus two copies of:
1. An annual progress report,
2. Financial status report, no more than 90 days after the end of
the budget period, and
3. Final financial report and performance report, no more than 90
days after the end of the project period.
Send all reports to Juanita Dangerfield, Grants Management
Specialist, Grants Management Branch, Procurement and Grants Office,
Announcement 98023, Centers for Disease Control and Prevention (CDC),
255 East Paces Ferry Road, NE., Mail Stop E-15, Room 300, Atlanta, GA
30305-2209.
For descriptions of the following Other Requirements, see
Attachment I:
1. AR98-1--Human Subjects Requirements
2. AR98-2--Inclusion of Women and Racial and Ethnic Minorities in
Research Requirements
3. AR98-4--HIV/AIDS Confidentiality Provisions
4. AR98-5--HIV Program Review Panel Requirements
5. AR98-6--Patient Care Prohibitions
6. AR98-9--Paperwork Reduction Act Requirements
7. AR98-10--Smoke-Free Workplace Requirements
8. AR98-11--Healthy People 2000
9. AR98-12--Lobbying Restrictions
I. Authority and Catalog of Federal Domestic Assistance Number
This program is authorized under the Public Health Service Act,
sections 317(k)(2) (42 U.S.C. 247b(k)(2)), 317E (42 U.S.C. 247b-6) and
318 of the Public Health Service Act, (42 U.S.C. 247c), as amended.
Regulations governing grants for STD research are codified in part 51b,
subparts A and F of Title 42, Code of Federal Regulations. The Catalog
of Federal Domestic Assistance numbers are 93.941, HIV Demonstration,
Research, Public and Professional Education; 93.943, Epidemiologic
Research Studies of Acquired Immunodeficiency Virus (AIDS) and Human
Immunodeficiency Virus (HIV) Infection in Selected Population Groups;
93.947, Tuberculosis Demonstration, Research, Public and Professional
Educations; and 93.978, Prevention Health Services--Sexually
Transmitted Diseases Research, Demonstrations, and Public Information
and Education Grants.
[[Page 18430]]
J. Where to Obtain Additional Information
To receive additional written information, call 1-888-472-6874. You
will be asked to leave your name, address, and phone number, and refer
to Announcement Number 98023. You will receive a complete program
announcement. CDC will not send application kits by facsimile or
express mail unless the cost for the latter is paid by the addressee.
This and other CDC announcements are also available through the CDC
homepage on the Internet. The address for the CDC homepage is http://
www.cdc.gov.
Business management technical assistance may be obtained from
Juanita Dangerfield, Grants Management Specialist, Grants Management
Branch, Centers for Disease Control and Prevention (CDC), Procurement
and Grants Office, 255 East Paces Ferry Road NE., Room 300, Mailstop E-
15, Atlanta, GA 30305, telephone (404) 842-6577, or facsimile at (404)
842-6513, or INTERNET address: jdd2@cdc.gov.
Programmatic technical assistance may be obtained from the National
Center for HIV, STDs and TB Prevention, Centers for Disease Control and
Prevention (CDC), Atlanta, GA 30303, for HIV, contact Carol Aloisio,
telephone (404) 639-0902; for STD, contact Sevgi Aral, telephone (404)
639-8259; for TB, contact Bess Miller, telephone (404) 639-8120.
Please refer to Announcement 98023 when requesting information and
submitting an application.
Dated: April 9, 1998.
Joseph R. Carter,
Acting Associate Director for Management and Operations, Centers for
Disease Control and Prevention (CDC).
[FR Doc. 98-9909 Filed 4-14-98; 8:45 am]
BILLING CODE 4163-18-P
